Scientific Pros Montgomery And Forslund Join Laurus Synthesis Inc.

Woburn MA, March 2, 2015 – Stuart Needleman, President, Laurus Synthesis Inc., announces that effective immediately two appointments to scientific leadership positions have been named at the company: Dr. Charles Montgomery, Vice President, Chemistry; and Dr. Raymond E. Forslund, Senior Director of Project Management.

As leader of Laurus Synthesis' scientific team based in Woburn, Dr. Montgomery is responsible for the delivery of chemistry and analytical development. The technical team that reports to him provides route scouting, process development and materials for preclinical and early clinical R&D. Dr. Forslund leads project management and is the key client interface for ongoing project communications, budget and progress. He also is the primary interface between Laurus Synthesis Inc. in Woburn and Laurus Labs PVT's Synthesis Business Unit in India for work occurring in India or jointly at the two locations. Together, Montgomery and Forslund lead the teams that are also responsible for the development of proposals.

Dr. Montgomery's distinguished career began at Glaxo-Wellcome Ltd., where he was a Research Chemist. He advanced to a series of growth positions at Albany Molecular Research Inc. (AMRI) in Syracuse, New York, where most recently he was the Director of Chemical Development. In addition, he is an Adjunct Professor of Chemistry at LeMoyne College in Syracuse and is the co-author of several scientific papers. He earned his undergraduate and doctorate degrees at the University of Edinburgh.

Dr. Forslund was a Project Manager and Lead Chemist at Vertex Pharmaceuticals early in his career, moving on to Senior Development Scientist positions. Subsequently, he joined Ironwood Pharmaceuticals (formerly Microbia) where he was Senior Manager of Operations. Dr. Forslund has been awarded several patents, is the author of numerous publications and is frequently called on as a presenter of scientific papers at industry events. He earned an MBA from Babson College and a Ph.D. in Organic Chemistry from the University of Illinois. His undergraduate work was completed at Hamilton College.

In making this announcement, Stuart Needleman stated that Dr. Montgomery and Dr. Forslund are both well known to the pharmaceutical and scientific communities in the Boston area. "Adding Charles and Ray to our Woburn team is in keeping with our plans to assemble a U.S. team of highly respected scientists who are distinguished by their records of innovating breakthrough chemistry. These proven scientific leaders are a great asset in all that we can do to surpass our clients' expectations of cost and time benefits with no compromise in quality."

For more information or to arrange an interview, contact Maria Garvey, Delfino Marketing Communications, at [email protected] or 914.747.1400.

* * * * *

About Laurus Synthesis Inc.

Laurus Synthesis Inc. offers specialized laboratory services from a new, state-of-the-art drug development facility in Woburn, Massachusetts. From this site, the company assists clients in advancing their concepts along the best path to their next milestone. Laurus Synthesis chemists and project managers provide process development, method development and impurity identification services, as well as route selection for API, intermediates and starting materials. In addition, a smooth technical transition to the products and services of Laurus Labs for scale-up and commercialization will be available as required. Laurus Synthesis Inc. is a subsidiary of Laurus Labs, one of India's top ten chemistry providers. For more information, please visit www.laurussynthesis.com.

About Laurus Labs

Based in Visakhapatnam, India, Laurus Labs Private Limited (Laurus) develops and manufactures active pharmaceutical ingredients (API), with a focus on anti-retroviral (ARV) and oncology products. The company supplies its APIs to several Indian and global pharmaceutical companies. In addition to the API business, Laurus offers contract research (chemical, analytical and formulation development) and manufacturing services to generic and innovative pharmaceutical companies. Laurus has world-class infrastructure, consisting of a state-of-the-art R&D and scale-up laboratory in Hyderabad and large-scale manufacturing facilities at Visakhapatnam. These facilities have been accredited by several international regulatory agencies including the US-FDA, UK-MHRA, Australian TGA and Korean FDA. The company has revenues approaching $250 million and currently employs 1,800+ people. For more information, please visit www.lauruslabs.com.

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.